Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ReNEW trial of elamipretide in dry age-related macular degeneration
ISRCTN59733193Phase 3Active, not recruiting
- Sponsor
- Stealth BioTherapeutics
- Start
- May 2024
- Modality
- Peptides
01
Overview
Phase 3, randomised, double-blind trial of elamipretide in age-related macular degeneration (AMD), sponsored by Stealth BioTherapeutics. Primary endpoint: Rate of change in macular photoreceptor loss at Week 48. Started May 2024; status: active, not recruiting.
02
Drugs
elamipretide
03
Conditions
age-related macular degeneration (AMD)
Beyond the preview
Go deeper on ISRCTN59733193.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN59733193.